Manuscript Number: AJO-09-1005

Title: Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions

Article Type: Correspondence

Keywords: bevacizumab; ranibizumab; macular degeneration

Corresponding Author: Andrea Messori, PharmD

Corresponding Author’s Institution: Area Vasta Centro - Toscana

First Author: Andrea Messori, PharmD

Order of Authors: Andrea Messori, PharmD; Valeria Fadda, PharmD; Sabrina Trippoli, PharmD
Dear Editor,

We should like to submit the enclosed paper (“Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions”) for publication in the Correspondence section of the journal.

Thank you for your kind attention.

Sincerely,

Andrea Messori
Laboratorio SIFO di Farmacoeconomia,
c/o Area Vasta Centro, via Guimaraes,
Macrolotto 2, Prato, 59100 Italy

Corresponding author:
Dr. Andrea Messori
Laboratorio SIFO di Farmacoeconomia,
c/o Area Vasta Centro,
via Guimaraes, Macrolotto 2,
Email labsifofe@gmail.com
Fax +390550935535
Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions

Andrea Messori, Valeria Fadda, Sabrina Trippoli

Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro, via Guimaraes, Macrolotto 2, Prato, 59100 Italy

Corresponding Author:

Dr. Andrea Messori

Laboratorio SIFO di Farmacoeconomia,
c/o Area Vasta Centro,
via Guimaraes, Macrolotto 2,
Email labsifo@gmail.com
Fax +390550935535
Subramanian et al. report that their randomized controlled trial was originally powered on the basis of an overall sample size of 135 patients (90 in the bevacizumab group and 45 in the ranibizumab group); however, the results presented in their article refer to a total of only 20 patients, which is less than 15% of the population planned at the beginning of the study.

It is therefore surprising to see that, despite the enrollment of a macroscopically insufficient population, the authors draw the conclusion that this controlled study “shows no difference in efficacy between the two treatments”.

On the contrary, these results do not allow to draw any conclusion about the relative efficacy of the two treatments. Furthermore, this paper might induce clinicians to think that bevacizumab and ranibizumab are equi-effective even though this conclusion is far from being demonstrated by these experimental results.

References

AJO Author Disclosure Statement

This form was adapted for the AJO from the New England Journal of Medicine.

Each author is required to fill out this form. The editor's interest extends to those areas relevant to the article that, broadly viewed, could be construed as constituting a conflict of interest or the appearance thereof. This form should be submitted at the time of the initial submission of the manuscript. The information will be used only by the Editorial Board of the AJO. It will not appear in print or on the AJO website. The footnote of the manuscript should still contain a short disclosure statement about each author.

If there is nothing to disclose, please so indicate.

Name  Andrea Messori E-Mail labsifofe@gmail.com

Manuscript Title Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions

Consulting fees or paid advisory boards (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤ USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Equity ownership/stock options (publicly or privately traded firms, excluding mutual funds)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤ USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Lecture fees when speaking at the invitation of a commercial sponsor (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤ USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Are you employed by the commercial entity that sponsored the study?  Yes  No

Grant support from industry? If yes complete next section. If none, indicate here: None

Current grant support. (include nonprofit/government entities):

<table>
<thead>
<tr>
<th>Entity</th>
<th>Total Amount</th>
<th>Years Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Do you have patents and/or royalties, serve as an expert witness, or perform other activities for a commercial sponsor? Please provide a brief description:

None

Type your name (signature not required): Andrea Messori  Date: 11/6/2009
Please save this file as a Word document and upload to your manuscript submission. A disclosure form is required for each author.
AJO Author Disclosure Statement
This form was adapted for the AJO from the New England Journal of Medicine.

Each author is required to fill out this form. The editor's interest extends to those areas relevant to the article that, broadly viewed, could be construed as constituting a conflict of interest or the appearance thereof. This form should be submitted at the time of the initial submission of the manuscript. The information will be used only by the Editorial Board of the AJO. It will not appear in print or on the AJO website. The footnote of the manuscript should still contain a short disclosure statement about each author.

If there is nothing to disclose, please so indicate.
Name  Valeria Fadda  E-Mail labsifoef@gmail.com

Manuscript Title Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions

Consulting fees or paid advisory boards (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Equity ownership/stock options (publicly or privately traded firms, excluding mutual funds)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Lecture fees when speaking at the invitation of a commercial sponsor (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Are you employed by the commercial entity that sponsored the study?  Yes ☐  No ☒

Grant support from industry? If yes complete next section. If none, indicate here: None ☒

Current grant support. (include nonprofit/government entities):

<table>
<thead>
<tr>
<th>Entity</th>
<th>Total Amount</th>
<th>Years Covered</th>
</tr>
</thead>
</table>

Do you have patents and/or royalties, serve as an expert witness, or perform other activities for a commercial sponsor? Please provide a brief description:

None

Type your name (signature not required): Valeria Fadda  Date: 11/6/2009
Please save this file as a Word document and upload to your manuscript submission. A disclosure form is required for each author.
AJO Author Disclosure Statement
This form was adapted for the AJO from the New England Journal of Medicine.

Each author is required to fill out this form. The editor's interest extends to those areas relevant to the article that, broadly viewed, could be construed as constituting a conflict of interest or the appearance thereof. This form should be submitted at the time of the initial submission of the manuscript. The information will be used only by the Editorial Board of the AJO. It will not appear in print or on the AJO website. The footnote of the manuscript should still contain a short disclosure statement about each author.

If there is nothing to disclose, please so indicate.
Name  Sabrina Trippoli E-Mail labsifofe@gmail.com

Manuscript Title Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions

Consulting fees or paid advisory boards (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Equity ownership/stock options (publicly or privately traded firms, excluding mutual funds)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Lecture fees when speaking at the invitation of a commercial sponsor (per year, for the past two years or the known future)

<table>
<thead>
<tr>
<th>Entity</th>
<th>None</th>
<th>≤USD 10,000</th>
<th>&gt; USD 10,000</th>
</tr>
</thead>
</table>

Are you employed by the commercial entity that sponsored the study? Yes ☐ No □

Grant support from industry? If yes complete next section. If none, indicate here: None ☒

Current grant support. (include nonprofit/government entities):

<table>
<thead>
<tr>
<th>Entity</th>
<th>Total Amount</th>
<th>Years Covered</th>
</tr>
</thead>
</table>

Do you have patents and/or royalties, serve as an expert witness, or perform other activities for a commercial sponsor? Please provide a brief description:

None

Type your name (signature not required):Sabrina Trippoli  Date:11/6/2009
Please save this file as a Word document and upload to your manuscript submission. A disclosure form is required for each author.